A comprehensive structure-activity analysis of protein kinase B-alpha (Akt1) inhibitors

被引:32
作者
Ajmani, Subhash [1 ]
Agrawal, Avantika [1 ]
Kulkarni, Sudhir A. [1 ]
机构
[1] NovaLead Pharma Pvt Ltd, Pride Purple Coronet, Pune 411045, Maharashtra, India
关键词
Protein kinase B; Akt inhibitors; QSAR; Anticancer; Kinase inhibitors; SELECTIVE INHIBITORS; B/AKT INHIBITORS; PKB INHIBITORS; POTENT; DISCOVERY; DESIGN; QSAR; CANCER; SAR; OPTIMIZATION;
D O I
10.1016/j.jmgm.2010.01.007
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Protein kinase B (PKB, also known as Akt) belongs to the AGC subfamily of the protein kinase superfamily. Akt1 has been reported as a central player in regulation of metabolism, cell survival, motility, transcription and cell-cycle progression, among the signalling proteins that respond to a large variety of signals. In this study an attempt was made to understand structural requirements for Akt1 inhibition using conventional QSAR, k-nearest neighbour QSAR and novel GQSAR methods. With this intention, a wide variety of structurally diverse Akt1 inhibitors were collected from various literature reports. The conventional QSAR analyses revealed the key role of Baumann's alignment independent topological descriptors along with other descriptors such as the number of hydrogen bond acceptors, hydrogen bond donors, rotatable bonds and aromatic oxygen (SaaOcount) along with molecular branching (chi3Cluster), alkene carbon atom type (SdsCHE-index) in governing activity variation. Further, the GQSAR analyses show that chemical variations like presence of hetero-aromatic ring, flexibility, polar surface area and fragment length present in the hinge binding fragment (in the present case fragment D) are highly influential for achieving highly potent Akt1 inhibitors. In addition, this study resulted in a k-nearest neighbour classification model with three descriptors suggesting the key role of oxygen (SssOE-index) and aromatic carbon (SaaCHE-index and SaasCE-index) atoms electro-topological environment that differentiate molecules binding to Akt1 kinase or PH domain. The developed models are interpretable, with good statistical and predictive significance, and can be used for guiding ligand modification for the development of potential new Akt1 inhibitors. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:683 / 694
页数:12
相关论文
共 36 条
[11]   Identification of a buried pocket for potent and selective inhibition of Chk1: Prediction and verification [J].
Foloppe, N ;
Fisher, LM ;
Francis, G ;
Howes, R ;
Kierstan, P ;
Potter, A .
BIOORGANIC & MEDICINAL CHEMISTRY, 2006, 14 (06) :1792-1804
[12]   Virtual docking approaches to protein kinase B inhibition [J].
Forino, M ;
Jung, D ;
Easton, JB ;
Houghton, PJ ;
Pellecchia, M .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (07) :2278-2281
[13]   QSAR Modeling using chirality descriptors derived from molecular topology [J].
Golbraikh, A ;
Tropsha, A .
JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES, 2003, 43 (01) :144-154
[14]   Role of the AKT kinase in expansion of multiple myeloma clones: effects on cytokine-dependent proliferative and survival responses [J].
Hsu, JH ;
Shi, YJ ;
Hu, LP ;
Fisher, M ;
Franke, TF ;
Lichtenstein, A .
ONCOGENE, 2002, 21 (09) :1391-1400
[15]   OPTIMIZATION BY SIMULATED ANNEALING [J].
KIRKPATRICK, S ;
GELATT, CD ;
VECCHI, MP .
SCIENCE, 1983, 220 (4598) :671-680
[16]   Expression, purification, characterization and homology modeling of active Akt/PKB, a key enzyme involved in cell survival signaling [J].
Kumar, CC ;
Diao, R ;
Yin, ZZ ;
Liu, YH ;
Samatar, AA ;
Madison, V ;
Xiao, L .
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2001, 1526 (03) :257-268
[17]   Dual blockade of EGFR and ERK1/2 phosphorylation potentiates growth inhibition of breast cancer cells [J].
Lev, DC ;
Kim, LS ;
Melnikova, V ;
Ruiz, M ;
Ananthaswamy, HN ;
Price, JE .
BRITISH JOURNAL OF CANCER, 2004, 91 (04) :795-802
[18]   Synthesis and structure-activity relationship of 3,4′-bispyridinylethylenes:: Discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer [J].
Li, Q ;
Woods, KW ;
Thomas, S ;
Zhu, GD ;
Packard, G ;
Fisher, J ;
Li, TM ;
Gong, JC ;
Dinges, J ;
Song, XH ;
Abrams, J ;
Luo, Y ;
Johnson, EF ;
Shi, Y ;
Liu, XS ;
Klinghofer, V ;
Jong, RD ;
Oltersdorf, T ;
Stoll, VS ;
Jakob, CG ;
Rosenberg, SH ;
Giranda, VL .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (07) :2000-2007
[19]   Discovery of trans-3,4′-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer:: Synthesis and biological evaluation [J].
Li, Q ;
Li, TM ;
Zhu, GD ;
Gong, JC ;
Claibone, A ;
Dalton, C ;
Luo, Y ;
Johnson, EF ;
Shi, Y ;
Liu, XS ;
Klinghofer, V ;
Bauch, JL ;
Marsh, KC ;
Bouska, JJ ;
Arries, S ;
De Jong, R ;
Oltersdorf, T ;
Stoll, VS ;
Jakob, CG ;
Rosenberg, SH ;
Giranda, VL .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (06) :1679-1685
[20]   Recent progress in the discovery of Akt inhibitors as anticancer agents [J].
Li, Qun .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2007, 17 (09) :1077-1130